Routine tests include full blood counts, liver, kidney, and thyroid function tests, cardiac profiles, and blood glucose testing, all of which support the detection, diagnosis, and ongoing monitoring of medical conditions.

gut-microbiome

Faecal immunochemistry test 

Eurofins Clinical Diagnostics Ireland partners with the HSE to offer the faecal immunochemistry test (FIT) as part of BowelScreen, Ireland's national bowel screening programme. In addition to the FIT, Eurofins laboratories in Ireland offer a range of gastroenterological tests, including the complementary Colosafe DNA test.

blood-science-laboratory
Other useful tests include

These tests can be ordered privately via a GP, Clinic or Hospital from Eurofins Biomnis Ireland.

-Prostate-specific antigen (PSA), a blood test to detect elevated levels of protein in the blood, which can indicate prostate cancer, but also benign conditions like an enlarged or inflamed prostate.

 

-Serum Protein Electrophoresis (SPEP) a blood test to detect or monitor disorders related to protein abnormalities, such as multiple myeloma, autoimmune diseases, and kidney or liver dysfunction. 

 

-Anti-Nuclear Antibody (ANA) test, a blood test to detect Auto -Immune activity. A positive ANA result does not confirm a specific autoimmune disease. Instead, it suggests the need for further, more specific tests and Eurofins offers all these follow-up (reflex) tests.

 

 

Cancer Monitoring Tests

Testicular Cancer - Blood test for 3 tumour markers that monitor diagnosed cases, Human Chorionic Gonadotropin( B-hCG), Alpha-fetoprotein (AFP), Lactate dehydrogenase (LDH). 

 

Lung Cancer - Tumors often trigger an inflammatory response, causing the body (and cancer cells ) to produce higher levels of Alpha-1 antitrypsin (A1AT). Elevated levels in the blood can signify the presence of a tumor. Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that  can lead to early-onset emphysema and COPD.

 

Chronic Pancreatitis - Ireland is among the highest in Europe according to Tallaght University Hospital (TUH) and the Department of Surgery at Trinity College Dublin (TCD. Monitor with Ca 19-9 & CEA (Carcinoembryonic Antigen) along with Liver Function tests.

 

Multiple Cancers 

The tests below are not screening tests. They can be used to plan treatment, see if treatment is working, help in cancer diagnosis and monitor if cancer is returning. They are used in conjunction with other tests. 

  • Cancer Antigen CA-125 is a protein normally found in small amounts in the body. It can be higher than normal with certain non-cancerous (benign) conditions and certain cancers such as ovarian, fallopian tube and primary peritoneal cancers.

 

  • Carbohydrate Antigen CA-19-9 - (also called sialyl Lewis-a) is normally found in small amounts in the body. Levels are higher with certain non-cancerous (benign) conditions and certain types of cancer,  pancreatic, gallbladder and bile duct cancers. However there is a % of people who don't produce CA19-9.

 

  • CA-15-3 is used to check if advanced breast cancer is responding to treatment or to see if it has come back after treatment. 

 

 

Alzheimer's Disease

There is an urgent need for earlier detection and effective treatments, to halt or slow Alzheimer’s Disease (AD) progression. AD is estimated to account for ~70% of 55 million dementia cases worldwide.

neurology-and-alzheimers-disease

Alzheimer's disease is characterised by a build-up of amyloid plaques and p-tau tangles. Amyloid plaques form over a long period of time when amyloid peptides accumulate and stick to the outside of neurons causing inflammation.

This inflammation causes cellular enzymes to modify the Tau protein (Tau), whose normal function is to stabilise the neuronal structure helping it to transport nutrients, waste, and chemical messengers. If Tau becomes abnormally modified (p-Tau), it can lose its function and form tangles within neurons that disrupt neuronal function.

Amyloid plaques can emerge decades before the onset of symptoms and plateau at symptom onset but if detected early, at the mild cognitive impairment stage rather than dementia stage, trials have shown that anti-amyloid therapies achieve better results. Tau tangles develop later and increase with symptom severity. Early detection is paramount to halt or slow AD.

APOE – a genetic test

The APOE gene instructs the body to make Apolipoprotein E, a protein that combines with fats to carry cholesterol through the bloodstream, manage lipid transport in the brain and help to clear the buildup of sticky amyloid plaques from the brain. Each individual inherits 2 APOE alleles (one from each parent). There are several different forms of APOE (epsilon (ε) 2, 3 and 4) which means that APOE genotype can vary from person to person. Having two copies of APOE ε4 is associated with a higher risk of Alzheimer’s than having one copy.

APOE genotype cannot fully predict who will or won’t develop Alzheimer’s but it is the strongest and most prevalent gene variation involved in more than half of all Alzheimer disease (AD) cases. However, some people with an APOE ε4 allele never develop the disease. Lifestyle and environmental factors such as exercise, diet, chemicals, or smoking can impact how genes work. Depending on the variation present in the APOE gene, it can cause disease by creating a protein that does not function properly, thereby affecting lipid transport, synaptic integrity and plasticity, glucose metabolism, plaque clearance and overall cerebrovascular function.

Expand_img

This test is available to order in Ireland

Sample type: EDTA whole blood

Test Methodology: PCR

Genetic Test: patient consent required

Turnaround Time: 4 weeks 

p-Tau 217

To date PET scans and cerebrospinal fluid (CSF) have been used to detect p-Tau and plaques but a blood test, p-Tau 217, can detect the pathologies (plaques & p-Tau) and predict the risk of developing symptoms related to Alzheimer's disease in the future.

A recent Nature Medicine study (Peterson K. et al, 2026) suggests an AD clock model using p-Tau 217 blood-based testing may predict the age of symptom onset because the accumulation of amyloid plaque and p-Tau tangles follow a remarkably consistent trajectory.

See below for important information

Expand_img

This test will be available to order Nov/Dec 2026

This test cannot be interpreted in subjects under the age of 54.

Elevations of p-Tau 217 may be seen in individuals with impaired kidney function associated with chronic kidney disease and should be interpreted with caution in these situations. A glomerular filtration rate (renal function) test is strongly recommended for interpreting the results. 

This test should not be performed in asymptomatic subjects to predict the risk of dementia.

This examination must be referred by a Neurologist or Geriatrician, or be accompanied by an MRI report or neurocognitive test results suggesting Alzheimer's disease.

Find a local laboratory

Eurofins Biomnis Ireland Limited

Three Rock Road, Sandyford Industrial Estate, Dublin,D18 A4C0, Ireland